Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer

被引：64

作者：

Markowska, Anna ^{[1
]}

Sajdak, Stefan ^{[2
]}

Markowska, Janina ^{[3
]}

Huczynski, Adam ^{[4
]}

机构：

[1] Karol Marcinkowski Med Univ, Dept Perinatol & Womens Dis, Poznan, Poland

[2] Karol Marcinkowski Med Univ, Dept Gynecol Surg, Poznan, Poland

[3] Karol Marcinkowski Med Univ, Dept Oncol, Poznan, Poland

[4] Adam Mickiewicz Univ, Fac Chem, Poznan, Poland

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2017年 / 142卷

关键词：

Ovarian cancer; Cancer stem cells; Anti-angiogenic therapy; Metformin; Salinomycin; IN-VITRO; TUMOR ANGIOGENESIS; TARGETED TREATMENT; DRUG-RESISTANCE; METFORMIN; SALINOMYCIN; APOPTOSIS; CYTOTOXICITY; BEVACIZUMAB; MECHANISMS;

D O I：

10.1016/j.ejmech.2017.06.030

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Failure in ovarian cancer therapy, following cytoreduction and chemotherapy, is related to the presence of cancer stem cells - a small subpopulation of cells resistant to chemotherapy and irradiation - in the tumour which may cause cancer relapse and manifestation of metastases. Therapies targeted at Cancer Stem Cells (CSCs), such as those employing metformin (a drug used in the treatment of diabetes type II) and salinomycin, an antibiotic isolated from Streptococcus calms bacteria, seem promising. Antiangiogenic therapy with bevacizumab was found to be effective in all phases of ovarian cancer treatment. The presence of CSCs has been associated with angiogenesis. Several CSC biomarkers correlate with the markers of angiogenesis and some signalling pathways, e.g. Notch, and are used by both CSCs and by pro-angiogenic factors. (C) 2017 Elsevier Masson SAS. All rights reserved.

引用

页码：87 / 94

页数：8

共 50 条

[21] Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Duan, Ping
Fan, Lili
Gao, Quansheng
Silwal, Bal Mukunda
Ren, Mulan
Shen, Yang
Qu, Wanglei
CURRENT DRUG TARGETS, 2017, 18 (10) : 1171 - 1178
[22] Ovarian cancer stem cells
Zeimet, A. G.
Reimer, D.
Sopper, S.
Boesch, M.
Martowicz, A.
Roessler, J.
Wiedemair, A. M.
Rumpold, H.
Untergasser, G.
Concin, N.
Hofstetter, G.
Mueller-Holzner, E.
Fiegl, H.
Marth, C.
Wolf, D.
Pesta, M.
Hatina, J.
NEOPLASMA, 2012, 59 (06) : 747 - 755
[23] Ovarian cancer stem cells
Bapat, Sharmila A.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2009, 30 (05) : 28 - 28
[24] Ovarian cancer stem cells
不详
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) : 1152 - 1152
[25] Angiogenesis as a strategic target for ovarian cancer therapy
Whitney A Spannuth
Anil K Sood
Robert L Coleman
Nature Clinical Practice Oncology, 2008, 5 : 194 - 204
[26] TARGETED THERAPY OF OVARIAN CANCER: BEYOND ANGIOGENESIS
Colombo, N.
ANNALS OF ONCOLOGY, 2014, 25
[27] Angiogenesis as a strategic target for ovarian cancer therapy
Spannuth, Whitney A.
Sood, Anil K.
Coleman, Robert L.
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (04): : 194 - 204
[28] Pancreatic cancer stem cells: new insights and perspectives
Jorge Dorado
Enza Lonardo
Irene Miranda-Lorenzo
Christopher Heeschen
Journal of Gastroenterology, 2011, 46 : 966 - 973
[29] Pancreatic cancer stem cells: new insights and perspectives
Dorado, Jorge
Lonardo, Enza
Miranda-Lorenzo, Irene
Heeschen, Christopher
JOURNAL OF GASTROENTEROLOGY, 2011, 46 (08) : 966 - 973
[30] GLIOBLASTOMA CANCER STEM CELLS AND ANGIOGENESIS
Colabianchi, Anna
Lama, Gina
D'Alessio, Ales Sio
Proietti, Gabriella
Angelucci, Cristiana
Mangiola, Annunziato
Maira, Giulio
Binda, Elena
Vescovi, Angelo
Sica, Gigliola
ANTICANCER RESEARCH, 2014, 34 (10) : 6166 - 6167

← 1 2 3 4 5 →